ArticleResearch (Washington, D.C.)2025

Visomitin Attenuates Pathological Bone Loss by Reprogramming Osteoclast Metabolism via the STAT3/LDHB Axis.

Putao Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.